SCHEMBL5523032

SCHEMBL5523032

N[C@@H]1[C@@H](OS(=O)(=O)O)[C@H](O)[C@@H](CO)O[C@@H]1O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
GAA P10253 1/20 0.38
LGALS3 P17931 1/20 0.37
CA2 P00918 7/20 0.37
CA12 O43570 6/20 0.37
CA9 Q16790 6/20 0.37
CA1 P00915 5/20 0.37
BLM P54132 1/20 0.37
RECQL P46063 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 1/20 0.36
SLC2A1 P11166 1/20 0.35
MAPK1 P28482 1/20 0.35
CXCL10 P02778 1/20 0.33
CXCL8 P10145 1/20 0.33
CCL2 P13500 1/20 0.33
CCL5 P13501 1/20 0.33
CXCL12 P48061 1/20 0.33
FGF1 P05230 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29535305 1.00 MAPT (0.39) MAPTGAALGALS3CA2CA12
SCHEMBL19667936 1.00 MAPT (0.39) MAPTGAALGALS3CA2CA12
SCHEMBL29535262 0.89 BLM (0.35) MAPTGAALGALS3CA2CA12
SCHEMBL29535395 0.89 BLM (0.35) MAPTGAALGALS3CA2CA12
SCHEMBL21753793 0.87 BLM (0.37) MAPTGAALGALS3CA2CA12
SCHEMBL29535705 0.87 BLM (0.37) MAPTGAALGALS3CA2CA12
SCHEMBL741519 0.86 SLC2A1 (0.42) MAPTLGALS3CA2CA12CA9
SCHEMBL150778 0.86 SLC2A1 (0.42) MAPTLGALS3CA2CA12CA9
SCHEMBL5318200 0.86 SLC2A1 (0.42) MAPTLGALS3CA2CA12CA9
SCHEMBL4294762 0.86 MAPT (0.43) MAPTGAALGALS3CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070042030-A1 Preparation for the application of agents in mini-droplets IDEA AG (DE) 2007-02-22 US disclosed
US-6329531-B1 FOR THERAPY OF ALZHEIMER'S DISEASE SCHERING AG (DE) 2001-12-11 US disclosed
US-6165500-A Preparation for the application of agents in mini-droplets IDEA AG (DE) 2000-12-26 US disclosed
EP-0942756-A2 OPTICAL DIAGNOSTIC AGENTS FOR DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY MEANS OF NEAR INFRA-RED RADIATION (NIR RADIATION) INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN (DE) 1999-09-22 EP disclosed
WO-1998022146-A2 OPTICAL DIAGNOSTIC AGENTS FOR DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY MEANS OF NEAR INFRA-RED RADIATION (NIR RADIATION) Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042030-A1 Preparation for the application of agents in mini-droplets FABP4, NPC1L1, LIPA MAPT 3617/4885GAA 702/4885LGALS3 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.